ArticleJournal of general internal medicine2026
Caution Is Warranted in Prescribing Ketamine for Mental Health.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.Fundamental & clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinics across the USA advertise ketamine as an alternative solution for mental health conditions. Ketamine has expanded into a multibillion-dollar industry, with three delivery models: (1) in-person clinics offering off-label racemic ketamine; (2) clinic visits for esketamine (Spravato); and (3) telehealth services prescribing off-label racemic ketamine. About half of the market encompasses telehealth using off-label prescribing. This article describes the legal changes behind the growth of telehealth-only providers, differences in patient monitoring requirements, and implications for patient safety. While providers can legally prescribe medications off-label, providers should consider three questions to determine whether off-label prescribing is clinically and ethically appropriate. Providers should evaluate: (1) whether sound evidence exists to prescribe; (2) whether drug benefits outweigh the risks; (3) and whether prescribing serves the patient's best interests. As a dissociative anesthetic, ketamine raises significant concerns regarding whether the purpose and function of the drug meet legal requirements for appropriate prescribing of controlled substances.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.